When was Denali Therapeutics founded?

Denali Therapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Denali Therapeutics located?

Denali Therapeutics is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Denali Therapeutics?

Ryan Watts of Denali Therapeutics.

How many employees does Denali Therapeutics have?

As of Mar 31, 2026, the latest employee count at Denali Therapeutics is 568.

Is Denali Therapeutics a funded company?

Denali Therapeutics is a funded company, having raised a total of $347M across 3 funding rounds to date. The company's 1st funding round was a $217M Series A round, raised on May 14, 2015.

When was the latest funding round of Denali Therapeutics?

Denali Therapeutics' latest funding was a $500M Post IPO round on Feb 27, 2024, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.37B in funding in 2026 to date.

What is the annual revenue of Denali Therapeutics?

Annual revenue of Denali Therapeutics is $331M as on Dec 31, 2023.

Is Denali Therapeutics a Neurology company?

The primary sectors of Denali Therapeutics are Neurology, Genomics, Clinical Genomics and Gastroenterology.

Where does Denali Therapeutics rank among its competitors?

Denali Therapeutics ranks 2nd amongst 817 active competitors, of which 284 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Juvenescence, which secured $76M in May, 2025.

Who are the top competitors of Denali Therapeutics?

Denali Therapeutics' top competitors include Human Longevity, Caris Life Sciences and Fulcrum Therapeutics. Among them, Juvenescence secured the most recent funding round in May, 2025.

Denali Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Sectors and market segments that Denali Therapeutics operate in

Denali Therapeutics serves in the Life Sciences market segments.The primary business model of Denali Therapeutics are:

Company Details

Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.

Website: www.denalitherapeutics.com/
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Public

Total Funding

$347M in 3 rounds

Latest Funding Round

Post IPO, Feb 27, 2024, $500M

Investors

Google Ventures & 11 more

Ranked

2^nd among 817 active competitors

Annual Revenue

$331M as on Dec 31, 2023

Employee Count

568 as on Mar 31, 2026

Investment & Acquisitions

Triller

Similar Companies

Human Longevity & 1076 more

Exit Details

Public

View Denali Therapeutics' full profile

Denali Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Denali Therapeutics Inc. CIN: 1714899 , United States, Active	Oct 13, 2013	$331M (As on Dec 31, 2023)	-	-
DENALI THERAPEUTICS, INC. CIN: 463872213 , United States, Active	Dec 31, 1999	-	410 (As on Dec 31, 2024)	-

Denali Therapeutics got listed on Dec 08, 2017.

Click here to take a look at Denali Therapeutics's IPO in detail

Denali Therapeutics has raised a total funding of $347M over 3 rounds. Its first funding round was on May 14, 2015. Denali Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of Denali Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 27, 2024	$500M	Post IPO	-	-	-	-
Aug 25, 2016	$130M	Series B	-	-	-	Baillie Gifford, Arch Venture Partners, F-Prime Capital, Alaska Permanent Fund, Flagship Pioneering
May 14, 2015	$217M	Series A	-	-	-	Arch Venture Partners, F-Prime Capital, Alaska Permanent Fund, Flagship Pioneering

Access funding benchmarks and valuations. Sign up today!

View details of Denali Therapeutics's funding rounds and investors

The founders of Denali Therapeutics are Marc Tessier Lavigne, Ryan Watts and Alexander Schuth.

Here are the details of Denali Therapeutics' key team members:

Marc Tessier Lavigne: Former Co-Founder of Denali Therapeutics.
Contact Info: 1 email address
Ryan Watts: Co-Founder & CEO of Denali Therapeutics.
Contact Info: 1 email address
Alexander Schuth: Co-Founder, Chief Operating and Financial Officer of Denali Therapeutics.
Contact Info: 2 email addresses

View details of Denali Therapeutics's Founder profiles and Board Members

Denali Therapeutics' employee count trend

Denali Therapeutics has 568 employees as of Mar 26. Here is Denali Therapeutics's employee count trend over the years:

Employee count trend for Denali Therapeutics

Uncover Denali Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Denali Therapeutics include Human Longevity, Caris Life Sciences and Fulcrum Therapeutics. Here is the list of Top 10 competitors of Denali Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Human Longevity 2013, San Diego (United States), Series B	Provider of precision medicine, preventative health assessments, and longevity care	$409M	Celgene, General Electric & 20 others	76/100
2nd	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Google Ventures, Baillie Gifford & 10 others	72/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
4th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Google Ventures, Foresite Capital & 15 others	71/100
5th	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
6th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
7th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Blackstone, Redmile Group & 16 others	67/100
8th	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	IDO Investments, Tencent & 39 others	67/100
9th	Amphista Therapeutics 2017, Cambridge (United Kingdom), Series B	Developer of targeted protein degradation medicines for pathogenic protein removal	$60.5M	Advent Life Sciences, Gilde Healthcare & 10 others	67/100
10th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Orbimed, Novartis & 10 others	66/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Denali Therapeutics's competitors? Click here to see the top ones

Denali Therapeutics has acquired Triller. Denali Therapeutics has not made any investments as of now.

Media has covered Denali Therapeutics for a total of 21 events in the last 1 year, 12 of them have been about company updates and 1 about partnerships.